IASLC Lung Cancer News (ILCN), April 2022
ILCN | English
Image For Activity Cover
Credit Offered
No Credit Offered
Table of Contents
  • TIL Therapy Endures for Carefully Selected Patients: A Q&A with Dr. Benjamin C. Creelan
  • Optimal Pathologic Staging of Lung Cancer Depends on More Than the Pathologist
  • Quality of Life After VATS and SABR for Early-stage Lung Cancer: The Lilac Study
  • Early Palliative Care: A European Perspective
  • Valuable Intersections: Maximizing Career Opportunities Arising From The Relationship Between Academia and Industry
  • IASLC Releases Position Statement on Air Pollution on Earth Day
  • In Brief for April 27, 2022
  • IASLC’s Global Reach a Strength on the Road to a Cure for Lung Cancer
  • Tumor Growth Rate as a Guide for Precision Lung Cancer Therapy
  • Patient Perspective: The Promise of Personalized Medicine
  • Cancer Misinformation: Its Impact on Patients and Mitigation Strategies
  • A Look at Veliparib Plus Chemotherapy for First-Line Treatment of Advanced NSCLC
  • Study Provides Insights That May Inform Prevention, Management of Mesothelioma
IASLC Lung Cancer News (ILCN) is the offical news source of the only global association dedicated to the multidisciplinary study of lung cancer, published bimonthly by the International Association for the Study of Lung Cancer (IASLC). 

Click here to link to Submission Guidelines.
Powered By